Tiny study hopes to unlock why some melanoma patients respond to immunotherapy

NCT ID NCT03225365

Completed Knowledge-focused Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 21, 2026 · Updated 3 times

Summary

This study tracked immune cell changes in 5 people with advanced melanoma who were taking nivolumab with or without ipilimumab. Researchers took blood and skin samples at several time points to compare immune responses between those who responded to treatment and those who did not. The goal was to better understand why immunotherapy works for some patients but not others.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors predict which patients will benefit from immunotherapy, leading to more personalized treatment plans.
What could go wrong: This is a very small, observational study with only 5 participants, so results may not apply broadly. It does not test a new treatment, only measures immune responses.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma metastatic melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC MELANOMA

Contacts and locations

Locations

Service de Dermatologie, Centre Hospitalier Lyon Sud (HCL)

Pierre-Bénite, 69310, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.